Sepracor Inc (SEPR) shares are on a bullish run with a recent earnings report adding fuel to the fire.
Company Description
Sepracor develops safer, purer, and more effective drugs to improve on already existing pharmaceuticals. The company develops compounds to improve a therapy’s efficacy, side-effects, or both.
Crushed Estimates
On Jul 24 Sepracor reported second-quarter results that included an 11% pop in revenue, up to $326 million. Earnings per share came in at 72 cents, almost double the Zacks Consensus Estimate of 38 cents.
This was the third consecutive surprise.
Raising Guidance
Management went on to raise full-year guidance, increasing estimated revenue to $1.25 billion, give or take $25 million. Earnings per share are expected to be between $2.55 and $2.90, up from between $2.10 and $2.70.
Estimtes Follow
After the release, the Zacks consensus estimate spiked to $2.88, from $2.41, for full-year 2009. This would be a year-over-year growth rate of 80%.
Analysts polled by Zacks also raised estimates for next year, which now average $2.90, up from $2.63.
Good Value
Share of SEPR are trading at 7 times earnings and with a PEG ratio of just 0.4. The average PEG ratio for its peers is a loft 2.6 times.
The Chart
SEPR has been on a great run over the past couple months of setting higher highs and higher lows. This is a great bullish trend hear. Take a look below.
